The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and ...

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize ...

It's a critical time to spotlight the dire health disparities affecting Black Americans, from premature deaths to maternal ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Patients were stratified into 4 risk groups based on recent heart failure hospitalization (HFH) and use of loop diuretics. 1 ...

FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

A report reveals that 45% of insured adults received unexpected medical bills for services they believed were covered.

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...